Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations

SAN DIEGO, April 23, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of transrenal molecular diagnostics, announced the appointment of Keith McCormick as head of commercial operations, effective April 16, 2012.

McCormick brings extensive pharmaceutical and diagnostic sales, marketing and operational experience. Most recently, he served as senior director of sales operations at bioTheranostics, Inc.  McCormick served as a member of the AviaraDx, Inc. executive team, where he built the commercial sales and marketing organization that successfully launched CancerTYPE ID, a molecular cancer classifier, as well as the Breast Cancer Index, a prognostic test for women with ER-positive, lymph-node negative breast cancer.  In September 2008, AviaraDx was sold to bioMerieux S.A. of France and renamed bioTheranostics.

Prior to AviaraDx, McCormick spent 10 years at Schering Plough and Biogen Idec, selling and marketing specialty pharmaceuticals. His career included assignments and leadership roles in sales, sales management, market research, product management, and new product planning.  McCormick began his healthcare career with Dianon Systems, a diagnostic specialty laboratory providing serum, tissue and genetic tests for cancer and inherited disorders.

"Keith's broad experience and in-depth understanding of the oncology and diagnostic markets will guide our commercial efforts," said Antonius Schuh, Ph.D., chief executive officer for Trovagene. "The company will focus its internal efforts on urine-based laboratory-developed tests for the detection of oncogene mutations in cancer patients. Keith's access to top-tier cancer centers and clinical opinion leaders, and his proven track record in building commercial organizations, will be critical components of Trovagene's success."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

SOURCE Trovagene, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED